ceralasertib治疗复发/难治性MDS和CMML的1b/2期研究
这项1b/2期研究评估了口服ATR抑制剂ceralasertib在44例复发/难治性MDS或CMML患者中的疗效与安全性,采用160mg每日两次的两种给药方案。总缓解率为29.5%,中位无进展生存期4.8个月,总生存期12个月,两种方案间无差异。常见≥3级不良事件包括血小板减少、贫血和中性粒细胞减少。
要点
- ceralasertib在复发/难治性MDS/CMML中总缓解率为29.5%,中位OS为12个月。
- 7on/7off方案较14on/14off方案可能减少第一周期血小板输注需求。
- 血清炎症细胞因子水平在ceralasertib暴露期间下降,RUNX1突变样本中该效应减弱。
核心结论
- ceralasertib 160mg每日两次在复发/难治性MDS和CMML中显示出一定疗效,7on/7off方案被确立为单药给药方案。
研究设计与样本
- 1b/2期研究,纳入44例可评估的复发/难治性MDS或CMML成人患者,ceralasertib 160mg每日两次,28天周期,两种方案:第1-14天或第1-7天和第15-21天。
主要发现
- 总缓解率为29.5%(13/44),包括1例完全缓解、5例骨髓完全缓解(其中2例中性粒细胞血液学改善)和7例血液学改善。
- 中位无进展生存期为4.8个月,中位总生存期为12个月。
- ≥3级不良事件包括血小板减少(n=13)、贫血(n=12)、中性粒细胞减少(n=9)、发热性中性粒细胞减少(n=9)、肺炎(n=6)和低氧(n=5)。
关键数值与推荐
- 总缓解率29.5%(13/44),完全缓解1例,骨髓完全缓解5例,血液学改善7例。
- 中位无进展生存期4.8个月,中位总生存期12个月。
- 7on/7off方案被确立为单药给药方案:160mg每日两次,第1-7天和第15-21天。
临床怎么用
- 对于复发/难治性MDS/CMML,ceralasertib可作为探索性治疗选择,但需关注血液学毒性。
- 7on/7off方案可能降低早期血小板输注需求,但需进一步验证。
局限性
- 样本量较小(44例可评估患者),为1b/2期单臂研究。
- 两种给药方案间疗效比较的P值未校正多重比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pre-mRNA splicing gene mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) induce R-loops, which trigger ataxia telangiectasis and Rad3-related kinase (ATR). We studied ceralasertib, an orally bioavailable ATR inhibitor, in adults with relapsed or refractory (R/R) MDS or CMML in a phase 1b/2 study 160mg twice daily during 28-day cycles on 2 dosing schedules: days 1 to 14 (14on/14off) or days 1-7 and 15-21 (7on/7off). Response rates and survival were estimated. Forty-four evaluable patients were treated. Grade ≥3 adverse events included thrombocytopenia (n = 13), anemia (n = 12), neutropenia (n = 9), febrile neutropenia (n = 9), pneumonia (n = 6), and hypoxia (n = 5). Thrombocytopenia requiring a platelet transfusion during the first cycle was reduced to 1 of 10 patients on 7on/7off compared with 8/16 patients on 14on/14off among patients with a baseline platelet count >50 × 109/L (P = .087). Overall response rate (ORR) was 29.5% (13/44 patients) and included 1 complete response (CR), 5 marrow CR (2 with hematologic improvement [HI] in neutrophils [HI-N]), and 7 with HI (HI in erythroid/red cells, n = 4; HI-N, n = 2; HI in platelets, n = 1). Median progression-free survival (PFS) was 4.8 months, and overall survival (OS) was 12 months. ORR (P = .72), PFS (P = .9), and OS (P = .65) did not differ between schedules. Splicing factor mutation variant allele frequencies (VAFs) remained stable while RUNX1 mutation VAFs typically increased at progression. Serum inflammatory cytokine levels (TNFRSF8 [CD30], TNF family members) decreased during ceralasertib exposure; this effect was blunted in RUNX1-mutant samples. Ceralasertib 160 mg twice daily on days 1-7 and 15-21 was established as monotherapy dosing. This trial was registered at www.clinicaltrials.gov as NCT03770429.
引用
- Brunner AM, Liu Y, Garcia JS, et al. A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML. Blood Adv. 2026. PMID: 42379235. doi:10.1182/bloodadvances.2026019848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。